Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin

Kenichiro Nagata, Nobuaki Egashira, Takaaki Yamada, Hiroyuki Watanabe, Yui Yamauchi, Ryozo Oishi

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Purpose Epirubicin is an antitumor drug, particularly used in the treatment of the breast cancer. The peripheral intravenous infusion of epirubicin frequently causes venous irritation such as, erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the epirubicin-induced venous irritation and to establish a suitable administration method of epirubicin. Methods The phlebitis scores (Visual Infusion Phlebitis score) were evaluated retrospectively using the collected nursing record. We analyzed the risk factor associated with venous irritation in 97 patients administered with epirubicin from December 2004 to September 2008. We subsequently changed the regimen of epirubicin and examined the incidence of venous irritation in 26 patients administered with epirubicin from August 2009 to March 2010. Results The phlebitis scores were significantly higher in the patients treated with ready-to-use solution compared with lyophilized powder (P=0.04). Based on this result, we switched the formulation of epirubicin to lyophilized powder. After the intervention, the phlebitis scores were significantly decreased (P=0.003). An ordinal logistic regression analysis revealed that use of ready-to-use solution was a significant predictor for venous irritation (odds ratio=3.70; 95%, confidence intervals, 1.29-11.45; P=0.02). Conclusions The use of ready-to-use solution was a risk factor for epirubicin-induced venous irritation. The change of formulation by pharmacist intervention decreased the risk of venous irritation.

元の言語英語
ページ(範囲)951-955
ページ数5
ジャーナルSupportive Care in Cancer
20
発行部数5
DOI
出版物ステータス出版済み - 5 1 2012

Fingerprint

Epirubicin
Phlebitis
Breast Neoplasms
Powders
Nursing Records
Erythema
Pharmacists
Intravenous Infusions
Antineoplastic Agents
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Pain
Injections

All Science Journal Classification (ASJC) codes

  • Oncology

これを引用

Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin. / Nagata, Kenichiro; Egashira, Nobuaki; Yamada, Takaaki; Watanabe, Hiroyuki; Yamauchi, Yui; Oishi, Ryozo.

:: Supportive Care in Cancer, 巻 20, 番号 5, 01.05.2012, p. 951-955.

研究成果: ジャーナルへの寄稿記事

Nagata, Kenichiro ; Egashira, Nobuaki ; Yamada, Takaaki ; Watanabe, Hiroyuki ; Yamauchi, Yui ; Oishi, Ryozo. / Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin. :: Supportive Care in Cancer. 2012 ; 巻 20, 番号 5. pp. 951-955.
@article{b122d4be327c435ea50c52221c8c76d7,
title = "Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin",
abstract = "Purpose Epirubicin is an antitumor drug, particularly used in the treatment of the breast cancer. The peripheral intravenous infusion of epirubicin frequently causes venous irritation such as, erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the epirubicin-induced venous irritation and to establish a suitable administration method of epirubicin. Methods The phlebitis scores (Visual Infusion Phlebitis score) were evaluated retrospectively using the collected nursing record. We analyzed the risk factor associated with venous irritation in 97 patients administered with epirubicin from December 2004 to September 2008. We subsequently changed the regimen of epirubicin and examined the incidence of venous irritation in 26 patients administered with epirubicin from August 2009 to March 2010. Results The phlebitis scores were significantly higher in the patients treated with ready-to-use solution compared with lyophilized powder (P=0.04). Based on this result, we switched the formulation of epirubicin to lyophilized powder. After the intervention, the phlebitis scores were significantly decreased (P=0.003). An ordinal logistic regression analysis revealed that use of ready-to-use solution was a significant predictor for venous irritation (odds ratio=3.70; 95{\%}, confidence intervals, 1.29-11.45; P=0.02). Conclusions The use of ready-to-use solution was a risk factor for epirubicin-induced venous irritation. The change of formulation by pharmacist intervention decreased the risk of venous irritation.",
author = "Kenichiro Nagata and Nobuaki Egashira and Takaaki Yamada and Hiroyuki Watanabe and Yui Yamauchi and Ryozo Oishi",
year = "2012",
month = "5",
day = "1",
doi = "10.1007/s00520-011-1166-0",
language = "English",
volume = "20",
pages = "951--955",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin

AU - Nagata, Kenichiro

AU - Egashira, Nobuaki

AU - Yamada, Takaaki

AU - Watanabe, Hiroyuki

AU - Yamauchi, Yui

AU - Oishi, Ryozo

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Purpose Epirubicin is an antitumor drug, particularly used in the treatment of the breast cancer. The peripheral intravenous infusion of epirubicin frequently causes venous irritation such as, erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the epirubicin-induced venous irritation and to establish a suitable administration method of epirubicin. Methods The phlebitis scores (Visual Infusion Phlebitis score) were evaluated retrospectively using the collected nursing record. We analyzed the risk factor associated with venous irritation in 97 patients administered with epirubicin from December 2004 to September 2008. We subsequently changed the regimen of epirubicin and examined the incidence of venous irritation in 26 patients administered with epirubicin from August 2009 to March 2010. Results The phlebitis scores were significantly higher in the patients treated with ready-to-use solution compared with lyophilized powder (P=0.04). Based on this result, we switched the formulation of epirubicin to lyophilized powder. After the intervention, the phlebitis scores were significantly decreased (P=0.003). An ordinal logistic regression analysis revealed that use of ready-to-use solution was a significant predictor for venous irritation (odds ratio=3.70; 95%, confidence intervals, 1.29-11.45; P=0.02). Conclusions The use of ready-to-use solution was a risk factor for epirubicin-induced venous irritation. The change of formulation by pharmacist intervention decreased the risk of venous irritation.

AB - Purpose Epirubicin is an antitumor drug, particularly used in the treatment of the breast cancer. The peripheral intravenous infusion of epirubicin frequently causes venous irritation such as, erythema, injection site pain, and phlebitis. The purpose of the present study was to investigate the risk factor associated with the epirubicin-induced venous irritation and to establish a suitable administration method of epirubicin. Methods The phlebitis scores (Visual Infusion Phlebitis score) were evaluated retrospectively using the collected nursing record. We analyzed the risk factor associated with venous irritation in 97 patients administered with epirubicin from December 2004 to September 2008. We subsequently changed the regimen of epirubicin and examined the incidence of venous irritation in 26 patients administered with epirubicin from August 2009 to March 2010. Results The phlebitis scores were significantly higher in the patients treated with ready-to-use solution compared with lyophilized powder (P=0.04). Based on this result, we switched the formulation of epirubicin to lyophilized powder. After the intervention, the phlebitis scores were significantly decreased (P=0.003). An ordinal logistic regression analysis revealed that use of ready-to-use solution was a significant predictor for venous irritation (odds ratio=3.70; 95%, confidence intervals, 1.29-11.45; P=0.02). Conclusions The use of ready-to-use solution was a risk factor for epirubicin-induced venous irritation. The change of formulation by pharmacist intervention decreased the risk of venous irritation.

UR - http://www.scopus.com/inward/record.url?scp=84863436359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863436359&partnerID=8YFLogxK

U2 - 10.1007/s00520-011-1166-0

DO - 10.1007/s00520-011-1166-0

M3 - Article

C2 - 21519948

AN - SCOPUS:84863436359

VL - 20

SP - 951

EP - 955

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 5

ER -